Centessa Pharmaceuticals PLC Sponsored ADR $CNTA Shares Acquired by Allostery Investments LP

Key Points

• Allostery Investments LP significantly increased its stake in Centessa Pharmaceuticals by 34.4%, making it the second largest holding in their portfolio, with a total value of approximately $5.5 million.
• Centessa Pharmaceuticals reported a loss of $0.38 earnings per share for the last quarter, missing analysts' expectations by $0.03.
• Insider trading activity saw CEO Saurabh Saha selling 55,000 shares of the company's stock, resulting in a 19.93% decrease in his ownership.

Allostery Investments LP grew its stake in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Free Report) by 34.4% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 382,524 shares of the company's stock after purchasing an additional 98,007 shares during the quarter. Centessa Pharmaceuticals makes up about 7.9% of Allostery Investments LP's holdings, making the stock its 2nd biggest position. Allostery Investments LP owned 0.29% of Centessa Pharmaceuticals worth $5,501,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. acquired a new position in shares of Centessa Pharmaceuticals in the 4th quarter valued at $31,000. Caitong International Asset Management Co. Ltd increased its holdings in shares of Centessa Pharmaceuticals by 15,209.5% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company's stock valued at $46,000 after acquiring an additional 3,194 shares during the period. Osterweis Capital Management Inc. acquired a new position in shares of Centessa Pharmaceuticals in the 1st quarter valued at $47,000. Barclays PLC increased its holdings in shares of Centessa Pharmaceuticals by 1,414.9% in the 4th quarter. Barclays PLC now owns 5,302 shares of the company's stock valued at $89,000 after acquiring an additional 4,952 shares during the period. Finally, Bank of New York Mellon Corp acquired a new position in shares of Centessa Pharmaceuticals in the 1st quarter valued at $147,000. Institutional investors and hedge funds own 82.01% of the company's stock.

Insiders Place Their Bets

In related news, insider Mario Alberto Accardi sold 15,000 shares of Centessa Pharmaceuticals stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $14.00, for a total transaction of $210,000.00. Following the transaction, the insider directly owned 216,485 shares of the company's stock, valued at $3,030,790. The trade was a 6.48% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Gregory M. Weinhoff sold 10,000 shares of the stock in a transaction on Wednesday, June 25th. The shares were sold at an average price of $13.86, for a total value of $138,600.00. Following the completion of the transaction, the insider owned 122,279 shares of the company's stock, valued at $1,694,786.94. This trade represents a 7.56% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 171,322 shares of company stock valued at $2,472,814 over the last three months. 7.09% of the stock is currently owned by company insiders.

Analyst Ratings Changes

CNTA has been the topic of a number of recent research reports. Chardan Capital reaffirmed a "buy" rating and issued a $30.00 target price on shares of Centessa Pharmaceuticals in a report on Tuesday, August 12th. Oppenheimer started coverage on shares of Centessa Pharmaceuticals in a research report on Friday, August 29th. They issued an "outperform" rating and a $40.00 price objective on the stock. Needham & Company LLC started coverage on shares of Centessa Pharmaceuticals in a research report on Wednesday, May 28th. They issued a "buy" rating and a $35.00 price objective on the stock. Wall Street Zen lowered shares of Centessa Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday, August 16th. Finally, Wells Fargo & Company started coverage on shares of Centessa Pharmaceuticals in a research report on Wednesday, September 3rd. They issued an "overweight" rating and a $31.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating and twelve have assigned a Buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $31.45.

Centessa Pharmaceuticals Price Performance

Shares of NASDAQ CNTA traded up $2.60 during trading on Monday, hitting $18.33. 2,071,609 shares of the company were exchanged, compared to its average volume of 977,808. The company has a debt-to-equity ratio of 0.32, a current ratio of 10.11 and a quick ratio of 10.12. The company has a market cap of $2.45 billion, a price-to-earnings ratio of -10.24 and a beta of 1.47. Centessa Pharmaceuticals PLC Sponsored ADR has a 1 year low of $9.60 and a 1 year high of $19.09. The firm's fifty day moving average price is $15.99 and its 200 day moving average price is $14.43.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.03). On average, sell-side analysts expect that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 earnings per share for the current fiscal year.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.